[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Children's Mercy Hospital Kansas City\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":540},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,20,0,[8,46,71,105,131,155,183,217,244,269,296,322,342,369,391,409,432,454,486,513],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100552185","ecmo-abi-detection-with-hyperfine-100552185",false,"NCT06469801","ECMO ABI Detection With Hyperfine","Low-Field Bedside MRI for Detection of Acute Brain Injury in Pediatric Extracorporeal Membrane Oxygenation","Inclusion Criteria\n\n* Participants that will be or are admitted to the Pediatric Intensive Care Unit, Cardiac Intensive Care Unit, or the Neonatal Intensive Care Unit\n* Ages 0-17 years\n* Participants that are at high risk for undergoing ECMO or are currently undergoing venovenous or venoarterial ECMO\n\n  • High risk participants include, but are not limited to:\n* Undergoing cardiac surgery\n* Congenital heart disease\n* Congenital diaphragmatic hernia\n* Refractory hypoxemic and\u002For hypercarbic respiratory failure\n* Vasoactive-refractory shock\n\nExclusion Criteria\n\n* Pregnancy\n* Active implants such as:\n\n  * Pacemaker\n  * Implanted defibrillator\n  * Implanted insulin pump\n  * Deep brain stimulator\n  * Vagus nerve stimulator\n  * Cochlear implant\n  * Programmable shunt\n* MRI incompatible surgical hardware (e.g., staples, screws, etc.)\n* Metal-containing tattoos or permanent make-up on head or neck\n* Suspected metal in eye, e.g.,\n* Former or current welders, metal workers, or individuals with a metal injury\n* Metal shrapnel\n* Passive implants are considered MRI-conditional","ALL","0 Days","17 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","The primary objective is to characterize the prevalence and type of ABI following cannulation for pediatric patients who require ECMO support. The secondary objective is to describe the time course and rates of ABI using ultralow-field bedside MRI relative to both duration of ECMO support and clinical imaging obtained in routine care of pediatric ECMO patients.",[27,28,29,30],"Acute Brain Injury","Extracorporeal Membrane Oxygenation Complication","Hypoxia-Ischemia, Brain","Stroke, Acute",[32],"Pediatric","RECRUITING","2026-06-30",{"date":36,"type":37},"2026-07-01","ACTUAL",{"date":39,"type":37},"2024-07-23",{"date":41,"type":21},"2027-12-01",{"name":43,"class":44},"Children's Mercy Hospital Kansas City","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":16,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":45},"100431831","phase-1-liver-adiposity-effects-on-pediatric-statin-100431831","NCT04903223","Liver Adiposity Effects on Pediatric Statin","Effects of Pediatric Liver Adiposity on Statin Disposition and Response","Inclusion Criteria:\n\n* 8-21 years\n* LDL cholesterol \\>130mg\u002Fdl (\\>95% percentile)\n* SLCO1B1 c.521TT genotype\n* Provide informed permission-assent(\\\u003C18 yrs.) or consent (≥18 yrs.)\n* Fasting overnight (\\~8 hrs.)\n* Enrolled in Cardiology Pharmacogenomic Repository\n\nExclusion Criteria:\n\n* Pregnancy\n* Non-fasting\n* Non-removable metal in body or MRI unsafe\n* Currently on statin therapy and unwilling to wash out of statin therapy for at least 4 weeks prior to Visit 1 and throughout the duration of the study.\n* Underlying unrepaired congenital or acquired cardiovascular defects or repaired congenital or acquired cardiovascular defects with hemodynamically significant residual disease.\n* History of underlying or laboratory evidence of underlying intestinal, metabolic, autoimmune, renal disease that can alter rosuvastatin disposition\\* (absorption, metabolism, distribution, or clearance)\n* Pharmacotherapy that interacts with statins (OATP1B1 inducers\u002Finhibitors) \\*\n* Inability to swallow a tablet\n* \\>5x the age-specific upper limit of normal for AST, ALT, total and conjugated bilirubin\n* Diarrhea in the last 24 hours\n* Anything that would exclude a participant from completing an MRI, such as pacemakers, claustrophobia, or body habitus (e.g., weight greater than 350 lbs.)",true,"8 Years","21 Years",{"count":57,"type":21},50,[59],"PHASE1","Single center, open-label, prospective investigation to quantify the effects hepatocellular fat has on hepatic statin transport and response in children and adolescents in obese and non-obese children and adolescents 8-21 years of age with normal, wild-type SLCO1B1 c.521TT genotype that are dosed rosuvastatin",[62],"Cholesterol; Lipidosis","2026-06-23",{"date":65,"type":37},"2026-06-25",{"date":67,"type":37},"2021-04-01",{"date":69,"type":21},"2027-03-31",{"name":43,"class":44},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":79,"maxAge":18,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":83,"conditions":84,"keywords":93,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":45},"100558681","phase-1-pharmacogenomic-contributions-to-trihexyphenidyl-biotransformation-and-response-in-children-with-dystonic-cerebral-palsy-100558681","NCT06554288","Pharmacogenomic Contributions to Trihexyphenidyl Biotransformation and Response in Children With Dystonic Cerebral Palsy","Pharmacogenomic Contribution to the Biotransformation of Trihexyphenidyl and Development of a Precision Dosing Model for Children With Dystonia and Cerebral Palsy","TRIKE2","Inclusion Criteria:\n\n* Ages 5-17 years of age\n* Diagnosis of cerebral palsy and dystonia causing interference\n* Parent\u002Flegal guardian of a child with a diagnosis of cerebral palsy and dystonia\n* Parent\u002Flegal guardian is willing and able to provide informed permission\u002Fassent for the study\n\nExclusion Criteria:\n\n* Previously or currently taking trihexyphenidyl\n* Patients turning 18 years of age within the study period (16 weeks from Study Day 1)\n* A language barrier for the patient that precludes communication and\u002For the ability to complete study-related requirements","5 Years",{"count":81,"type":21},40,[59],"This study looks at how a medicine called trihexyphenidyl works in children with dystonic cerebral palsy. The study aims to understand how trihexyphenidyl is broken down and used in the body of pediatric patients and whether this is impacted by a person's genetics. Information from this study will also be used to design future clinical trials.",[85,86,87,88,89,90,91,92],"Pediatric Disorder","Genetic Predisposition","Dystonia, Secondary","Dystonia","Cerebral Palsy, Dystonic-Rigid","Cerebral Palsy, Dyskinetic","Trihexyphenidyl Adverse Reaction","Pharmacogenomic Drug Interaction",[32,94,88,95,96],"Cerebral Palsy","Pharmacogenomics","Trihexyphenidyl","2026-06-19",{"date":99,"type":37},"2026-06-24",{"date":101,"type":37},"2024-10-15",{"date":103,"type":21},"2029-12-31",{"name":43,"class":44},{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":113,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":22,"phases":116,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":127,"leadSponsor":129,"locationsCount":130},"100641159","dry-needling-and-quad-strength-after-anterior-cruciate-ligament-reconstructon-100641159","NCT07657195","Dry Needling and Quad Strength After Anterior Cruciate Ligament Reconstructon","Effects of Dry Needling on Quadriceps Muscle Strength in Acute Post-Operative Anterior Cruciate Ligament Reconstruction With Quadriceps Autograft in the Pediatric Population.","ACLR","Inclusion Criteria:\n\n* Status post subacute quadriceps autograft 6 weeks or less\n* Ages 10-20 years\n* English and\u002For Spanish speaking\n\nExclusion Criteria:\n\n* History of surgery on the knee or hip on the testing lower extremity.\n* Any surgical intervention to other ligamentous or meniscus structures during time of ACLR\n* Any post-surgical complications such as infection\n* Current pregnancy","10 Years","20 Years",{"count":81,"type":21},[24],"Dry needling is a skilled intervention provided by trained physical therapists to treat pain, myofascial dysfunction, and a variety of other diagnosis. While there is research demonstrating the benefits of dry needling in reduction of pain and improvement in strength, research in regards the pediatric population is very limited. I recently completed a retrospective chart review regarding dry needling trends and outcomes in the pediatric orthopedic population. We now know the pediatric population is tolerating this treatment and seeing benefits. Physical therapists are already pushing the boundaries and finding additional benefits in the use of dry needling with our current patients. A diagnosis frequently seen in sports medicine is surgical reconstruction of the anterior cruciate ligament (ACL). Over the last couple of years, therapists have seen an increase in the use of quadriceps tendon autograft for reconstruction following ACL tears due to lower incidence rate of retears. These patients have been struggling to regain strength of the quadriceps to meet desired outcomes. The quadricep muscles are one of the major stabilizers of the knee and with a reduction in strength places the patient at a significant increase of retear.\n\nSubjects will be categorized into an experimental group (dry needling intervention + physical therapy) or the control group (physical therapy only) with a N of 20 in each group.\n\nThe goal for this research is to determine if dry needling use in the subacute phase of post-operative ACLR following quadriceps autograft can assist with increasing quad strength and improve post-surgical outcomes.",[119,120,121],"Anterior Cruciate Ligament Reconstruction Rehabilitation","Dry Needling","Strength","NOT_YET_RECRUITING","2026-06-15",{"date":125,"type":37},"2026-06-18",{"date":36,"type":21},{"date":128,"type":21},"2027-06-30",{"name":43,"class":44},3,{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":16,"minAge":137,"maxAge":18,"enrollmentInfo":138,"targetDuration":4,"studyType":22,"phases":139,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":152,"leadSponsor":154,"locationsCount":4},"100636811","tubeclear-system-evaluation-in-pediatric-patients-100636811","NCT07570537","TubeClear System Evaluation in Pediatric Patients","Inclusion Criteria:\n\n* Males or females under the age of 18 for the entire duration of the study procedure and follow up with an occluded (partial\u002Fsluggish or fully blocked) EAD\n* Indwelling EAD must be NE, NG, NJ tube composed of PVC or polyurethane and is 6-18 FR, 38-140 cm\n* NG tube being used as a J tube inserted through a G tube and is 6-18 Fr; 38-140 cm\n* G and J tubes 10-18 Fr; 20-36cm\n* Specific GJ tubes: G-Jet, MIC, and MIC-KEY Tubes that are size 14-22Fr and have a jejunal length of 15-45cm\n\nExclusion Criteria:\n\n* Wards of the State\n* Positive urine pregnancy test\u002Fpregnant females or inability to take a pregnancy test\n* Any active gastrointestinal abnormalities, including but not limited to infections, inflammation, and\u002For recent abdominal surgery (except for recent gastrostomy placement) or trauma\n* Constant dependency on the EAD for glucose source\n* Unable to tolerate water volume needed for EAD flush\n* Unknown length of EAD\n* Attending physician declines enrollment based on clinical judgment\n* Subject turns 18 years of age during study duration\n* Very low birth weight (\\\u003C1.5kg)","0 Years",{"count":5,"type":21},[24],"Enteral access devices (EADs) provide necessary hydration, nutrition, and medications to numerous patients in hospitals across the United States. When patient's EAD becomes clogged it can delay administration of important nutrition and medications which can cause adverse effects such as malnutrition, and dehydration, especially in pediatric patients. Traditional methods of unclogging EADs can require the use of special enzymes or chemicals but these produce a variable rate of success. The TubeClear system has been developed to help alleviate the need for use of special enzymes or chemicals and to provide a quick, safe alternative for those with a clogged or sluggish EAD all while at the patient's bedside. This system prevents the need for subsequent exposure to radiation and contrast media for confirmation of EAD location after replacement.",[142,143,144,145,146,147],"Clogged Enteral Access Devices","Occluded Enteral Access Devices","Enteral Nutrition","Enteral Access Device","Tube Feeding","Gastric Feeding Tubes","2026-06-04",{"date":150,"type":37},"2026-06-05",{"date":36,"type":21},{"date":153,"type":21},"2028-06-01",{"name":43,"class":44},{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":163,"enrollmentInfo":164,"targetDuration":4,"studyType":22,"phases":166,"briefSummary":167,"conditions":168,"keywords":172,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":45},"100638999","regulating-together-for-intellectual-disability-and-autism-a-group-behavioral-therapy-for-for-emotion-dysregulation-100638999","NCT07624448","Regulating Together for Intellectual Disability and Autism: A Group Behavioral Therapy for for Emotion Dysregulation","Adapting a Group Intervention for Emotion Dysregulation in Autism and Intellectual Disability","RT-ID","Child Participant Inclusion Criteria:\n\n* Males, females, or non-binary youth between 8 and 12 years of age\n* Confirmed diagnosis of Autism Spectrum Disorder (ASD)\n* Confirmed diagnosis of Intellectual Disability\n* Fluent in spoken English.\n* Use of flexible phrase speech or greater\n* Meeting clinically significant emotion dysregulation criteria\n* Willing to participate in twice weekly 90-minute sessions\n* Family is willing to keep prescribed psychiatric medication and outside behavioral interventions stable\n* Parent, guardian, or legally authorized representative (LAR) must provide written permission on behalf of the participant\n\nChild Participant Exclusion Criteria:\n\n* Initiation of new psychosocial intervention within 30 days prior to first day of treatment\n* Presence of physical aggression in the child directed towards a peer outside the home (i.e., non-siblings) that resulted in injury within 30 days prior to screening. Other significant disruptive, aggressive, self-injurious, or sexually inappropriate behavior felt to be dangerous or overly disruptive to the group sessions will be reviewed by the study team on an individual basis.\n* Presence of comorbid major neuropsychiatric illness warranting other treatment approaches\n* Presence of any major sensory impairment that would limit participating in the material including blindness or uncorrected hearing loss\n\nCaregiver Inclusion Criteria:\n\n* Age ≥ 18 years\n* Lives and cares for their child with ASD+ID for \\> 50% of the year\n* Fluent in spoken English.\n* Willing to participate in twice weekly 90-minute sessions, including one virtual session weekly\n\nCaregiver Exclusion Criteria:\n\n-Presence of any major sensory impairment that would limit participating in the material including blindness or uncorrected hearing loss","12 Years",{"count":165,"type":21},10,[24],"The goal of this study is to help children with autism and a co-occurring intellectual disability and their families learn practical strategies for managing issues like irritability, aggression, and other challenging behaviors. The main objective of this study is:\n\nTo adapt current Regulating Together materials to create an outpatient group program for emotion dysregulation in autism and co-occurring intellectual disability (ASD + ID) that will improve psychosocial outcomes for youth with ASD + ID.",[169,170,171],"Autism","Intellectual Disabilities With Other Behavioral Symptoms","Intellectual Disability",[169,173,174,175],"intellectual disability","emotion dysregulation","aggression","2026-06-03",{"date":150,"type":37},{"date":179,"type":21},"2026-10",{"date":181,"type":21},"2027-12",{"name":43,"class":44},{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":16,"minAge":113,"maxAge":191,"enrollmentInfo":192,"targetDuration":4,"studyType":22,"phases":194,"briefSummary":195,"conditions":196,"keywords":199,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":45},"100627912","a-feasibility-trial-of-virtual-reality-neurofeedback-for-adolescents-with-migraine-100627912","NCT07454798","A Feasibility Trial of Virtual Reality Neurofeedback for Adolescents With Migraine","Feasibility of Home-based Immersive Neurofeedback Self-regulation Training (INSeRT) for Youth With Migraine","INSeRT","Inclusion Criteria:\n\n* Age 10-16 years (inclusive)\n* Diagnosis of migraine (with or without aura, or chronic migraine) by a qualified headache specialist\n* At least 4 migraine headaches per month\n* Presence of headache-free periods between migraine episodes\n\nExclusion Criteria:\n\n* Significant physical, psychiatric, or developmental conditions that would limit ability to participate in study procedures\n* Clinically elevated Pediatric Vestibular Symptoms Questionnaire (PVSQ) score (\\>0.68) or new\u002Fworsening vestibular symptoms prior to randomization\n* Initiation of a new migraine preventive medication within 4 weeks prior to randomization\n* Current participation in behavioral treatment for migraine (e.g., cognitive behavioral therapy or biofeedback)\n* History of epilepsy or photosensitive seizures","16 Years",{"count":193,"type":21},38,[24],"The goal of this clinical trial is to learn whether a home-based virtual reality (VR) neurofeedback program is feasible and acceptable for adolescents with migraine. The study will also explore whether the program may improve headache-related outcomes.\n\nThe main questions it aims to answer are:\n\nIs it feasible to enroll, randomize, and retain adolescents with migraine in this study?\n\nDo participants complete the VR sessions and study procedures as intended?\n\nAre there preliminary signals that the VR neurofeedback program may improve headache-related disability and symptoms?\n\nResearchers will compare Immersive Neurofeedback Self-Regulation Training (INSeRT), which uses brain activity recorded from a wearable electroencephalogram (EEG) headband to guide the VR experience, to a comparison VR program that presents immersive imagery without neurofeedback or guided relaxation training.\n\nParticipants will:\n\nComplete a 4-week baseline period that includes headache logs, questionnaires, and a laboratory EEG assessment\n\nBe randomly assigned to one of two VR programs\n\nComplete VR sessions at home three times per week for 4 weeks\n\nComplete questionnaires at the end of treatment and again approximately 3 months later\n\nRepeat the laboratory EEG assessment at the end of treatment",[197,198],"Migraine","Headache Disorders, Primary",[200,201,202,203,204,205,206,207,208,209],"Pediatric migraine","Adolescents","Neurofeedback","Virtual reality","Electroencephalogram","EEG","Cortical excitability","Self-regulation","Biofeedback","Mind-body therapy","2026-06-01",{"date":176,"type":37},{"date":213,"type":37},"2026-05-13",{"date":215,"type":21},"2028-05-31",{"name":43,"class":44},{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":223,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":16,"minAge":225,"maxAge":18,"enrollmentInfo":226,"targetDuration":4,"studyType":22,"phases":227,"briefSummary":228,"conditions":229,"keywords":231,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":45},"100638258","regulating-together-for-prader-willi-syndrome-a-group-behavioral-therapy-for-emotion-dysregulation-100638258","NCT07607730","Regulating Together for Prader-Willi Syndrome: A Group Behavioral Therapy for Emotion Dysregulation","Adapting a Group Intervention for Emotion Dysregulation in Prader-Willi Syndrome","RT-PWS","Child Participant Inclusion Criteria:\n\n* Ages 13-17.5 years\n* Confirmed genetic diagnosis of Prader-Willi Syndrome\n* Fluent in spoken English\n* Adolescent's use of flexible phrase speech or greater\n* Meeting clinically significant emotional dysregulation criteria\n* Willing to participate in weekly 90-minute group sessions\n* Family is willing to keep prescribed psychiatric medication and outside behavioral interventions stable\n* Parent, guardian, or legally authorized representative must provide written permission on behalf of the participant\n\nChild Participant Exclusion Criteria:\n\n* Initiation of new psychosocial intervention within 30 days prior to first day of treatment\n* Presence of physical aggression in the adolescent directed towards a peer outside the home that resulted in injury within 30 days prior to screening\n* Presence of comorbid major neuropsychiatric illness warranting other treatment approaches\n* Presence of any major sensory impairment that would limit participating in the material including blindness or uncorrected hearing loss\n\nCaregiver Inclusion Criteria:\n\n* Age ≥ 18 years\n* Lives and cares for their child with PWS for \\> 50% of the year\n* Fluent in spoken English\n* Willing to participate in twice weekly 90-minute sessions, including one virtual session weekly\n\nCaregiver Exclusion Criteria:\n\n-Presence of any major sensory impairment that would limit participating in the material including blindness or uncorrected hearing loss","13 Years",{"count":165,"type":21},[24],"The goal of this study is to help teens with Prader-Willi Syndrome (PWS) and their families learn practical strategies for managing issues like irritability, meltdowns, and anxiety. The main objective of the study is:\n\nTo adapt current Regulating Together materials to create an outpatient group program for emotion dysregulation in Prader-Willi Syndrome (PWS) that will improve psychosocial outcomes for youth with PWS.",[230],"Prader-Willi Syndrome",[230,232,175,233,234,235],"Emotion dysregulation","anxiety","depression","hyperphagia","2026-05-26",{"date":238,"type":37},"2026-05-28",{"date":240,"type":21},"2026-08",{"date":242,"type":21},"2027-11",{"name":43,"class":44},{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":250,"eligibilityCriteria":251,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":18,"enrollmentInfo":252,"targetDuration":4,"studyType":22,"phases":254,"briefSummary":255,"conditions":256,"keywords":4,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":268,"locationsCount":4},"100638702","portable-mri-for-pediatric-hypoxic-ischemic-brain-injury-100638702","NCT07577336","Portable MRI for Pediatric Hypoxic Ischemic Brain Injury","Ultralow-Field Portable MRI for Detection of Pediatric Hypoxic Ischemic Brain Injury","pMRI for pHIBI","Inclusion Criteria\n\n* Patients hospitalized in the Pediatric Intensive Care Unit, Cardiac Intensive Care Unit, or the Neonatal Intensive Care Unit\n* Ages 0-17 years at study enrollment\n* Acute neurologic deficit suspected secondary to Hypoxic Ischemic Brain Injury (HIBI) or patients at high risk for HIBI\n\nExclusion Criteria\n\n* Pregnancy\n* Active implants such as\n\n  * Pacemaker\n  * Implanted defibrillator\n  * Implanted insulin pump\n  * Deep brain stimulator\n  * Vagus nerve stimulator\n  * Cochlear implant\n  * Programmable shunt\n* MRI incompatible surgical hardware (e.g., staples, screws, etc.)\n* Metal-containing tattoos or permanent make-up on head or neck\n* Suspected metal in eye, e.g.,\n* Former or current welders, metal workers, or individuals with a metal injury\n* Metal shrapnel",{"count":253,"type":21},200,[24],"This study will evaluate the sensitivity and specificity of low field portable MRI (pMRI) for detection of hypoxic ischemic brain injuries in pediatric patients compared to clinically obtained neuroimaging to define pediatric diagnostic limitations and to determine the diagnostic capabilities of this neuroimaging modality following optimization of image acquisition. The results of this study will help determine optimal clinical implementation opportunities in pediatric patients.",[27,257,258,259,260,261],"Hypoxia, Brain","Ischemia, Brain","Brain Injuries","Trauma, Brain","Stroke","2026-05-03",{"date":264,"type":37},"2026-05-11",{"date":266,"type":21},"2026-06",{"date":181,"type":21},{"name":43,"class":44},{"id":270,"slug":271,"hasResults":11,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":275,"eligibilityCriteria":276,"healthyVolunteers":11,"sex":16,"minAge":163,"maxAge":277,"enrollmentInfo":278,"targetDuration":4,"studyType":22,"phases":280,"briefSummary":281,"conditions":282,"keywords":284,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":295,"locationsCount":45},"100517257","remote-cardiac-rehab-for-adolescents-with-congenital-heart-disease-100517257","NCT06015191","Remote Cardiac Rehab for Adolescents With Congenital Heart Disease","Remotely Delivered Cardiac Rehabilitation for Adolescents With Congenital Heart Disease","Remote-CaRe","Inclusion Criteria:\n\n1. Age 12-19 years old\n2. Male or Female\n3. Diagnosed with one of three congenital heart diseases:\n\n   Univentricular heart with Fontan Palliation Tetralogy of Fallot with transannular patch Dextro-transposition of the great arteries with arterial switch operation\n4. Primary Cardiology clearance for exercise participation\n5. Internet access in their homes\n6. Available for in-home exercise between 4-7pm on at least 3 days of the Monday-Friday work week\n7. English Speaking\n8. Achieving maximal effort on a cardiopulmonary exercise test, defined as RER ≥1.1 and\u002For in the judgement of the supervising exercise physiologist, a maximal effort was achieved but exercise capacity is limited by musculoskeletal deconditioning.\n\nExclusion Criteria:\n\n1. Physically or developmentally unable to perform outcomes assessments or participate in moderate-to-vigorous intensity physical activity\n2. Participating in \\> 15 MET-hours per week (mean weekly average over the past 12-months) of organized athletic\u002Fexercise activity (not including school physical education class).\n3. Height less than 132cm\n4. Pregnancy or planned surgery or procedure (excluding outpatient, non-cardiac procedures) within the 12-week study period.\n5. Meeting at least 1 exercise test safety or screening criteria on most recent exercise test (pre-study) or baseline outcomes visit exercise test\n6. Presence of significant cardiac dysfunction that would impair safe participation in moderate-to-vigorous intensity exercise\n7. Significant changes baseline echocardiogram or most recent clinical echocardiogram (from past clinical echocardiogram) such as decrease in ventricular and\u002For valvar function, new obstruction, or any new structural abnormalities\n8. Uncontrolled or poorly controlled asthma\n9. Presence of implanted cardioverter-defibrillator\n10. Pacemaker with rate-responsive function initiated\n11. Reliance on ventricular assist device\n12. Prescribed milrinone medication\n13. Listed for heart transplantation\n14. Active engagement in hormone replacement for gender transition","19 Years",{"count":279,"type":21},74,[24],"The goal of this randomized controlled trial is to evaluate the effectiveness of video conferencing for the delivery of live-supervised, real-time cardiac rehabilitation (CR) exercise training to groups of adolescents with congenital heart disease (CHD) in their homes. Participants will be randomized to either the remote cardiac rehab (RCR) group or active control group. The RCR group will participate in live, group-based exercise training (3-5 participants per exercise session), in their homes 3 days per week for 45 minutes over 12-weeks. Exercise sessions will be led and supervised by a live health coach via telehealth video technology. The active control group will be provided informational handouts on health exercise for their cardiac diagnosis. The primary aim is to compare between group changes (0-12-weeks) in cardiorespiratory fitness (VO2peak). Secondary aims are to compare between group changes (0-12-weeks) in cardiac function (echocardiography), lean body mass, and physical frailty. Exploratory aims will compare between group changes (0-12-weeks) in physical function, quality of life, skeletal muscle function, and physical activity self-efficacy. Additionally, exploratory aims will explore the impact of demographic characteristics, program participation, program satisfaction, and daily physical activity on changes in cardiorespiratory fitness.",[283],"Congenital Heart Disease in Children",[285,286,287,288],"Exercise","Cardiac Rehabilitation","Physical Activity","Telehealth","2026-04-28",{"date":291,"type":37},"2026-05-04",{"date":293,"type":37},"2023-08-31",{"date":181,"type":21},{"name":43,"class":44},{"id":297,"slug":298,"hasResults":11,"nctId":299,"briefTitle":300,"officialTitle":301,"acronym":4,"eligibilityCriteria":302,"healthyVolunteers":11,"sex":16,"minAge":303,"maxAge":18,"enrollmentInfo":304,"targetDuration":4,"studyType":305,"phases":4,"briefSummary":306,"conditions":307,"keywords":311,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":45},"100628202","vibandz-feasibility-study-100628202","NCT07458568","ViBandz Feasibility Study","ViBandz Feasibility Study in the Neurological Pediatric Population","Inclusion Criteria (Children):\n\n* Children of ages 6 months to 17 years old\n* Neurologic conditions resulting in abnormal movement of at least one extremity\n* Appointment scheduled in CM PT\u002FOT clinic that would include targeted focal vibration as a standard of care\n\nExclusion Criteria (Children):\n\n* Wards of the state\n\nInclusion Criteria (Parent\u002FLAR):\n\n* Parent or Legally Authorized Representative of a child with inclusion criteria above\n* English-speaking\n\nExclusion Criteria (Parent\u002FLAR):\n\n* Non-English speaking","6 Months",{"count":20,"type":21},"OBSERVATIONAL","This is a single site, mixed methods, feasibility study of the ViBandz device at a Midwest pediatric tertiary care hospital in a physical and occupational therapy clinic.",[308,309,310],"Pediatrics","Neurologic Dysfunction","Vibration Therapy",[312,313],"pediatrics","vibration therapy","2026-04-22",{"date":316,"type":37},"2026-04-27",{"date":318,"type":37},"2026-04-07",{"date":320,"type":21},"2026-12-31",{"name":43,"class":44},{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":326,"acronym":4,"eligibilityCriteria":327,"healthyVolunteers":11,"sex":16,"minAge":137,"maxAge":328,"enrollmentInfo":329,"targetDuration":4,"studyType":22,"phases":331,"briefSummary":332,"conditions":333,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":341,"locationsCount":45},"100484034","low-field-magnetic-resonance-imaging-assessment-with-outpatients-100484034","NCT05582785","Low Field Magnetic Resonance Imaging Assessment With Outpatients","Inclusion Criteria\n\nOutpatients at CMH Adele Hall Radiology ages 0 days to 22 years are eligible for enrollment.\n\nExclusion Criteria\n\nNo additional sedation will be given as part of this study and that sedation, if already administered, will not be altered for study purposes.\n\nAny patient who has a contraindication to having an MRI, such as:\n\nNon-MRI conditional implanted device or device that is not able to be removed for MRI examination","22 Years",{"count":330,"type":21},500,[24],"The objective of the study is to perform imaging assessments of an early stage magnetic resonance imaging (MRI) system on patients using low field magnetic strength.",[334],"Conditions Requiring a Brain Magnetic Resonance Imaging, Head Computerized Tomography, or Head Ultrasound","2026-02-04",{"date":337,"type":37},"2026-02-06",{"date":339,"type":37},"2022-09-01",{"date":320,"type":21},{"name":43,"class":44},{"id":343,"slug":344,"hasResults":11,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":348,"eligibilityCriteria":349,"healthyVolunteers":11,"sex":16,"minAge":350,"maxAge":4,"enrollmentInfo":351,"targetDuration":4,"studyType":22,"phases":353,"briefSummary":354,"conditions":355,"keywords":357,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":45},"100564501","focused-acceptance-and-commitment-therapy-fact-100564501","NCT06630000","Focused Acceptance and Commitment Therapy (FACT)","Focused Acceptance and Commitment Therapy (FACT) for Parents of Children With Pediatric Feeding Disorder","FACT","Inclusion Criteria:\n\n* 1\\) Must be a parent aged 18+ (primary caregiver) of 2-6-year-old child with PFD\n* 2\\) Child must be receiving outpatient PFD treatment at CMH\n* 3\\) The parent must have a clinically significant elevation on at least one measure of parent MH (using established clinical cutoffs). Parents will be included regardless of whether the child has a new diagnosis or established diagnoses\n\nExclusion Criteria:\n\n* 1\\) Parent has significant cognitive impairments\n* 2\\) Parent does not speak English\n* 3\\) Parent unable to obtain high speed internet at home","18 Years",{"count":352,"type":21},80,[24],"This is a randomized clinical trial of Focused Acceptance and Commitment Therapy (FACT) vs. an attention-control condition (placebo) for improving the mental health of parents of children with pediatric feeding disorder.\n\nThe goal of this clinical trial is to compare two programs in parents of children with pediatric feeding disorders.\n\nThe main question\\[s\\] it aims to answer are:\n\nFACT will result in clinically meaningful reductions in Mental Health(MH) problems among parents of children with Pediatric Feed Disorder (PFD) Identify factors that impact the feasibility of FACT delivery\n\nParticipants will asked to participate in one of two programs focused on parents of children with pediatric feeding disorders. The participants will also be asked to complete a battery of questionnaires at four timepoints during the study. The parents will be asked to video record a meal time three times during study.\n\nResearchers will compare the FACT group with a control group to see if FACT will result in clinically meaningful change in parent stress and anxiety, and parent use of positive mealtime behaviors.",[356],"Pediatric Feeding Disorders",[358,359,360],"Feeding","Mental Health","Parents","2026-01-13",{"date":363,"type":37},"2026-01-15",{"date":365,"type":37},"2024-10-14",{"date":367,"type":21},"2028-01-01",{"name":43,"class":44},{"id":370,"slug":371,"hasResults":11,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":4,"eligibilityCriteria":375,"healthyVolunteers":11,"sex":16,"minAge":191,"maxAge":376,"enrollmentInfo":377,"targetDuration":4,"studyType":22,"phases":379,"briefSummary":380,"conditions":381,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":390,"locationsCount":45},"100546087","implementing-the-spotlight-aq-platform-in-adolescent-young-adult-16-25-years-old-type-1-diabetics-t1d-100546087","NCT06390371","Implementing the Spotlight AQ Platform in Adolescent\u002F Young Adult (16-25 Years Old) Type 1 Diabetics (T1D)","Spotlight AQ Randomized Controlled Trial of the Spotlight AQ Survey Platform to Evaluate Its' Efficacy and Applicability in a Clinic Setting.","Inclusion Criteria:\n\n* 16-25 years old\n* Patients diagnosed with T1D for at least 6 months\n* On any diabetes treatment\n* Using a Continuous Glucose Monitor (CGM)\n* Willing\u002F able to use Spotlight AQ tool\n* Able to give verbal assent\n* Patients \\& parents\u002Fcaregiver speak English\u002F Spanish fluently\n* Patients in the Children's Mercy Kansas City Hospital or Boston Children's Hospital network\n\nExclusion Criteria:\n\n* \\\u003C16 years old or \\>25 years old\n* Mental illness that could seriously reduce their ability to participate in the study\n* Lack of capacity\n* In another T1D intervention study","25 Years",{"count":378,"type":21},60,[24],"The goal of this clinical trial is to compare the Spotlight AQ survey platform to the standard of care (SOC) pre-clinic assessment in adolescents \\& young adults (16-25 years old) with Type 1 Diabetes (T1D).\n\nThe main questions it aims to answer are:\n\n* Does using the Spotlight AQ survey in clinic decrease the A1c in the people who use it?\n* Do patients and healthcare providers like using the spotlight AQ survey?\n\nParticipants will use the Spotlight AQ survey before coming in to two standard of care T1D clinic visits Participants will fill out surveys describing how they feel about using the Spotlight AQ survey. Some participants may be asked to do an interview to talk about how they feel about the Spotlight AQ survey.",[382],"Type 1 Diabetes Mellitus","2026-01-08",{"date":385,"type":37},"2026-01-09",{"date":387,"type":37},"2024-05-27",{"date":389,"type":21},"2026-12",{"name":43,"class":44},{"id":392,"slug":393,"hasResults":11,"nctId":394,"briefTitle":395,"officialTitle":395,"acronym":4,"eligibilityCriteria":396,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":328,"enrollmentInfo":397,"targetDuration":4,"studyType":22,"phases":399,"briefSummary":400,"conditions":401,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":45},"100410819","low-field-and-high-field-magnetic-resonance-imaging-assessments-on-pediatric-patients-100410819","NCT04629469","Low Field and High Field Magnetic Resonance Imaging Assessments on Pediatric Patients","Inclusion Criteria\n\nInpatients at CMH Adele Hall ages 0 days to 22 years are eligible for enrollment.\n\nExclusion Criteria\n\nNo additional sedation will be given as part of this study and that sedation, if already administered, will not be altered for study purposes.\n\nAny patient who has a contraindication to having an MRI, such as:\n\nNon-MRI conditional implanted device or device that is not able to be removed for MRI examination",{"count":398,"type":21},250,[24],"Hyperfine Research, Inc. has taken advantage of technological advances and developed an MRI device that is not only portable, but also uses a very-low magnetic field strength, \\[less than 0.2 Tesla or approximately 10 times less\\] than the field strength of conventional devices. This critical difference allows HRI to address MRI's core challenges by, first, operating at very low magnetic field strengths, eliminating the need for special rooms or shielding. Second, there are minimal safety concerns regarding ferrous metals near the system, as the field strength is too low to attract metal objects. The removal of metal, including items such as jewelry, belts, etc. from clothing and person, prior to being scanned, is unnecessary. Third, the design constraints faced by conventional MRI systems are lifted at low magnetic field and an open device has been designed to minimize anxiety that may come with claustrophobic patients. All of this is possible while still providing image quality that is clinically relevant to a wide variety of fields, including radiology, neurology, pediatrics, emergency medicine, and others.",[334],"2026-01-06",{"date":383,"type":37},{"date":405,"type":37},"2020-10-01",{"date":407,"type":21},"2030-12",{"name":43,"class":44},{"id":410,"slug":411,"hasResults":11,"nctId":412,"briefTitle":413,"officialTitle":413,"acronym":414,"eligibilityCriteria":415,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":416,"targetDuration":4,"studyType":22,"phases":418,"briefSummary":419,"conditions":420,"keywords":422,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":431,"locationsCount":45},"100541018","phase-1-improving-drug-dosing-and-outcomes-for-single-ventricle-patients-with-fontan-associated-liver-disease-100541018","NCT06324396","IMProving DRug Dosing and Outcomes for Single VEntricle Patients With Fontan Associated Liver Disease","IMPROVE-FALD","Inclusion Criteria:\n\n* \\> 8 years\n* Status Post Fontan Completion\n* Ability to provide informed permission-assent (\\\u003C18 years) or consent (≥18 years)\n* Fasting overnight (\\~8 hours)\n\nExclusion Criteria:\n\n* Pregnancy\n* Non-fasting\n* Non-removable metal in body or where magnetic resonance imaging (MRI) is considered unsafe\n* Sildenafil and\u002For Pravastatin therapy within last 2 months\n* History of underlying or laboratory evidence of underlying intestinal, metabolic, autoimmune, renal disease that can alter Sildenafil and Pravastatin disposition (absorption, metabolism, distribution, or clearance)\n* Pharmacotherapy that interacts with Sildenafil (cytochrome P450 3A4 and P450 3A5 (CYP3A4\u002F5) inducers\u002Finhibitors) and\u002For Pravastatin (organic anion transporting polypeptide (OATP1B1) inducers\u002Finhibitors)\n* Inability to swallow a tablet\n* \\>5X the age-specific upper limit of normal for aspartate aminotransferase (AST) and alanine aminotransferase (ALT), total and conjugated bilirubin\n* Diarrhea in the last 24 hours \\*History of solid organ transplantation",{"count":417,"type":21},15,[59],"This is a single center, open-label, prospective, investigation to quantify the effects liver congestion and fibrosis has on hepatic drug metabolism and transport in children, adolescents, and young adults with Fontan circulation.",[421],"Fontan Circulation",[423,424],"Fontan","FALD","2025-12-31",{"date":427,"type":37},"2026-01-02",{"date":429,"type":37},"2024-03-01",{"date":320,"type":21},{"name":43,"class":44},{"id":433,"slug":434,"hasResults":11,"nctId":435,"briefTitle":436,"officialTitle":437,"acronym":4,"eligibilityCriteria":438,"healthyVolunteers":11,"sex":16,"minAge":439,"maxAge":440,"enrollmentInfo":441,"targetDuration":4,"studyType":22,"phases":442,"briefSummary":443,"conditions":444,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":447,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":453,"locationsCount":45},"100517478","investigating-fit-and-satisfaction-of-the-prone-positioner-100517478","NCT06018064","Investigating Fit and Satisfaction of the Prone Positioner","Investigating the Fit and Satisfaction of an Innovative Device - Prone to Excellence: A Tummy Time Device Prone Positioner for Infants With Medical Complexities Including Artificial Airways: A Design Pilot Study","Inclusion Criteria:\n\n* Inpatient infants located on the Pediatric Intensive Care Unit (PICU) or (Neonatal Intensive Care Unit (NICU) or being seen in the Vent clinic at Children's Mercy with tracheostomies between the ages of \\>44 weeks gestational age to 24 months of age with various size\u002Fweights of infants.\n* Any race\u002Fethnicity\n* English speaker\n* Males and females\n* Caregivers\n* Children's Mercy (CM) Occupational Therapists (OTs), Physical Therapists (PTs), Speech Therapists (STs) who have not seen the new prone positioner device.\n\nExclusion Criteria:\n\n* Infants \\> 24 months of age\n* Infants medically unstable as determined by attending physician in the PICU\u002FNICU or Vent Clinic\n* Infants with recent cardiac or abdominal surgery who have precautions or complications related to their surgery.\n* Infants with weightbearing restrictions\u002Ffractures in their upper extremities.\n* Non-English speakers \\* Wards of the state","44 Weeks","24 Months",{"count":20,"type":21},[24],"The goal of this clinical trial is to learn about the use of the Prone Positioner in pediatric patients with tracheostomies (trachs). The main question\\[s\\] it aims to answer are:\n\n* What is the fit and satisfaction of the device?\n* Does the device fulfill the goal of allowing infants with trachs participate in tummy time\n* What aesthetic feedback will the study team receive on the prone positioner from families, therapists, and nursing staff.\n\nParticipants will be placed in the Prone Positioner, they will be monitored for their comfort\u002Fsatisfaction with use, and how well they are able to be receive ventilation while in the device. Parents of these infants, as well as healthcare providers, will be surveyed on thoughts\u002Fsuggestions for the Prone Positioner.",[445],"Infant Development","2025-12-01",{"date":448,"type":37},"2025-12-05",{"date":450,"type":37},"2023-09-21",{"date":452,"type":21},"2028-09",{"name":43,"class":44},{"id":455,"slug":456,"hasResults":11,"nctId":457,"briefTitle":458,"officialTitle":459,"acronym":460,"eligibilityCriteria":461,"healthyVolunteers":11,"sex":16,"minAge":225,"maxAge":55,"enrollmentInfo":462,"targetDuration":4,"studyType":22,"phases":463,"briefSummary":465,"conditions":466,"keywords":472,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":479,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":485,"locationsCount":45},"100478383","early-phase-1-naltrexone-neuroimaging-in-teens-with-eating-disorders-100478383","NCT05509257","Naltrexone Neuroimaging in Teens With Eating Disorders","Development of a Pharmacodynamic Biomarker of Opioid Antagonism in Adolescents With Eating Disorders","NN-RCT","Inclusion Criteria:\n\n* Adolescents and young adults aged 13-21 years\n* Eating disorder diagnosis characterized by binge eating and\u002For purging (eg, Anorexia Nervosa-Binge\u002FPurge, Bulimia Nervosa, Binge Eating Disorder, Other Specified Feeding\u002FEating Disorder) using Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-V) criteria.\n* Stable medication regimen (no dose or drug changes in the past 4 weeks)\n* Participant and parent\u002Flegal guardian (if under 18 years) are willing and able to provide informed permission\u002Fassent\u002Fconsent for the study\n\nExclusion Criteria:\n\n* Pregnant (via UCG)\n* Prior hypersensitivity reaction to naltrexone (e.g., anaphylaxis)\n* Non-removable metal in the body that is magnetic resonance imaging incompatible\n* Current naltrexone use\n* Self-reported opioid use in the past 7 days\n* A language barrier (e.g., non-English speaking) for the participant that precludes communication and\u002For ability to complete all study-related requirements.",{"count":378,"type":21},[464],"EARLY_PHASE1","Using a randomized, placebo-controlled, crossover study, this study will evaluate functional magnetic resonance imaging (fMRI) as a pharmacodynamic biomarker of opioid antagonism in adolescents with eating disorders. The hypothesis is that fMRI will be able to detect acute reward pathway modulation by naltrexone (an opioid antagonist) in pre-defined regions of interest (anterior cingulate cortex, nucleus accumbens, dorsolateral prefrontal cortex).",[467,468,469,470,471],"Eating Disorders","Binge Eating","Purging (Eating Disorders)","Bulimia Nervosa","Anorexia Nervosa, Atypical",[32,473,474,475,476,477],"Adolescent","Eating Disorder","Neuroimaging","Naltrexone","Pharmacodynamic Biomarker","2025-11-20",{"date":480,"type":37},"2025-11-25",{"date":482,"type":37},"2022-09-17",{"date":484,"type":21},"2027-06",{"name":43,"class":44},{"id":487,"slug":488,"hasResults":11,"nctId":489,"briefTitle":490,"officialTitle":490,"acronym":4,"eligibilityCriteria":491,"healthyVolunteers":11,"sex":16,"minAge":492,"maxAge":18,"enrollmentInfo":493,"targetDuration":4,"studyType":22,"phases":494,"briefSummary":496,"conditions":497,"keywords":499,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":506,"startDateStruct":508,"completionDateStruct":510,"leadSponsor":512,"locationsCount":45},"100607936","phase-4-safety-and-efficacy-of-measles-mumps-rubella-vaccination-in-pediatric-heart-transplantation-patients-100607936","NCT07195032","Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Pediatric Heart Transplantation Patients","Inclusion Criteria:\n\n* Received a heart transplant\n* At least 1 year after transplant\n* At least 1 year after antibody-mediated rejection treatment (intravenous immune globulin, rituximab, bortezomib, plasmapheresis, carfilzomib, eculizumab, daratumumab)\n* At least 1 year from anti-thymocyte globulin\n* At least 6 months after pulse dose steroid treatment or basiliximab treatment\n* No history of MMR vaccination OR History of MMR vaccination but seronegativity for measles at time of inclusion\n* Clinically well\n\nExclusion Criteria:\n\n* History of repeated infections necessitating adjustment in immunosuppression to non-standard regimen, including single agent immunosuppression and modified trough levels.\n* History of anaphylactic reaction to MMR vaccination","1 Year",{"count":378,"type":21},[495],"PHASE4","The study is an interventional, non-randomized assessment of safety and efficacy of live Measles, Mumps and Rubella (MMR) vaccine in subjects aged 12-months to 17 years who have undergone heart transplantation. Subjects who provide permission\u002Fassent will receive the commercial MMR vaccine according to product indication and labeling.",[498],"Heart Transplant Infection Prevention",[500,501,502,503,504],"Measles","Mumps","Rubella","Live vaccine","Heart transplant","2025-09-19",{"date":507,"type":37},"2025-09-26",{"date":509,"type":37},"2025-09-11",{"date":511,"type":21},"2027-09-11",{"name":43,"class":44},{"id":514,"slug":515,"hasResults":11,"nctId":516,"briefTitle":517,"officialTitle":518,"acronym":519,"eligibilityCriteria":520,"healthyVolunteers":11,"sex":521,"minAge":163,"maxAge":114,"enrollmentInfo":522,"targetDuration":4,"studyType":22,"phases":523,"briefSummary":524,"conditions":525,"keywords":528,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":532,"lastUpdatePostDateStruct":533,"startDateStruct":535,"completionDateStruct":537,"leadSponsor":539,"locationsCount":45},"100580230","phase-4-bleeding-patterns-in-sequential-and-continuous-progesterone-supplementation-in-adolescents-with-turner-syndrome-100580230","NCT06834594","Bleeding Patterns in Sequential and Continuous Progesterone Supplementation in Adolescents With Turner Syndrome","Bleeding Patterns in Sequential and Continuous Progesterone Supplementation in Adolescents With Turner Syndrome: A Non-randomized Prospective Trial (The BOOST Study)","BOOST","Inclusion Criteria:\n\n* Diagnosis of Turner Syndrome and Primary Ovarian Insufficiency.\n* Prescribed adult dosing\\* of transdermal or oral estradiol for estrogen replacement therapy.\n\n  \\*Adult dosing of will be defined per published clinical practice guidelines from the 2023 International Turner Syndrome Meeting (i.e. 50-200μg\u002Fday of transdermal estradiol, or (i.e. 50-200μg\u002Fday of transdermal estradiol or 2-4mg\u002Fday oral estradiol).\n* Have achieved menarche.\n\nExclusion Criteria:\n\n* Disclosure of sexual activity and desire for contraception.\n* Having a levonorgestrel-releasing intrauterine device or etonogestrel arm implant in place.\n* Having received depot medroxyprogesterone within one year prior to study recruitment.\n* Non-English or non-Spanish speaking.","FEMALE",{"count":81,"type":21},[495],"This is a single-site open label non-randomized study comparing effects of sequential versus continuous use of progesterone supplementation amongst Turner Syndrome (TS) patients with primary ovarian insufficiency (POI) prescribed hormone replacement therapy (HRT).",[526,527],"Turner Syndrome","Primary Ovarian Insufficiency (Poi)",[529,530,531],"Turner syndrome","Primary ovarian insufficiency","Hormone replacement therapy","2025-08-27",{"date":534,"type":37},"2025-09-04",{"date":536,"type":37},"2025-07-31",{"date":538,"type":21},"2026-07-31",{"name":43,"class":44},""]